| View |
|
BRP-049-01
|
Filgrastim
|
Grastigen
|
300 mcg/0.5 mL
|
Solution For Injection (IV/SC)
|
Colony Stimulating Factors
|
Reliance Life Sciences Pvt. Ltd. (Plant II)
|
India
|
Automatic Renewal
|
08 July 2022
|
28 September 2027
|
| View |
|
BRP-049-02
|
Filgrastim
|
Timgrastix
|
300mcg/0.5mL
|
Solution For Injection (Iv/Sc)
|
Hematopoietic Growth Factor
|
Reliance Life Scienve Pvt. Ltd. (Pant II)
|
India
|
Automatic Renewal
|
08 July 2022
|
28 September 2027
|
| View |
|
BRP-049-03
|
Filgrastim
|
Cellacyte
|
300 mcg/0.5 mL
|
Solution for Injection (IV/SC)
|
Colony Stimulating Factors
|
Reliance Life Sciences Pvt. Ltd. (Plant II)
|
India
|
Automatic Renewal
|
08 July 2022
|
28 September 2027
|
| View |
|
BRP-050
|
Recombinant Alfa-2B
|
Reliferon
|
3 million IU/0.5 mL
|
Solution For Injection (Im/Sc)
|
Antineoplastic and Immunomodulating Agents (Interferons)
|
Reliance Life Sciences Pvt. Ltd.
|
India
|
Automatic Renewal
|
12 September 2022
|
21 November 2028
|
| View |
|
BRP-052
|
Human Normal Immunoglobulin
|
Immunorel
|
5% (50 mg/mL)
|
Solution for Infusion IV
|
Immunoglobulin
|
Reliance Life Sciences Pvt. Ltd.
|
India
|
Renewal
|
24 May 2019
|
07 March 2029
|
| View |
|
BRP-052-01
|
Human Normal Immunoglobulin
|
Proivig
|
5% (50 mg/mL)
|
Solution for Infusion IV
|
Immunoglobulins
|
Reliance Life Sciences Pvt. Ltd.
|
India
|
Renewal
|
22 November 2023
|
07 March 2029
|
| View |
|
BRP-052-02
|
Human Normal Immunoglobulin
|
Immubulin
|
5% (50 mg/mL)
|
Solution for Infusion (IV)
|
Immunoglobulins
|
Reliance Life Sciences Pvt. Ltd.
|
India
|
Renewal
|
23 November 2023
|
07 March 2029
|
| View |
|
BRP-052-03
|
Human Normal Immunoglobulin
|
Normglubin
|
5% (50 mg/mL)
|
Solution For Iv Infusion
|
Immunoglobulins
|
Reliance Life Scienve Pvt. Ltd.
|
India
|
Renewal
|
23 November 2023
|
07 March 2029
|
| View |
|
BRP-052-04
|
Human Normal Immunoglobulin
|
Gamma-I.V.
|
5% (50mg/mL)
|
Solution For Infusion (I.V.)
|
Immunoglobulins
|
Reliance Life Science Pvt. Ltd.
|
India
|
Renewal
|
19 November 2023
|
07 March 2029
|
| View |
|
BRP-053
|
Reteplase (Recombinant Tissue Plasminogen Activator)
|
Mirel
|
10 Units
|
Lyophilized Powder For Injection (Iv)
|
Antithrombotic
|
Reliance Life Sciences Pvt. Ltd. (Plant II)
|
India
|
Automatic Renewal
|
03 October 2022
|
18 July 2028
|
| View |
|
BRP-054
|
Biphasic Isophane Insulin Human (Recombinant DNA Origin)
|
Wosulin-30/70
|
100IU/mL
|
Suspension for Injection (SC)
(30% Regular Insulin Human/70% Isophane Insulin Human)
|
Intermediate-acting Insulin
|
Wockhardt Ltd.
|
India
|
Renewal
|
28 January 2019
|
10 February 2029
|
| View |
|
BRP-054-01
|
Biphasic Isophane Insulin Human (Recombinant DNA Origin)
|
Glysolin 30/70
|
100IU/mL
|
Suspension for Injection (SC)
(30% Regular Insulin Human/70% Isophane Insulin Human)
|
Intermediate-acting Insulin
|
Wockhardt Ltd.
|
India
|
Renewal
|
16 November 2023
|
10 February 2029
|
| View |
|
BRP-054-02
|
Biphasic Isophane Insulin Human (Recombinant DNA Origin)
|
None
|
100 IU/mL
|
Suspension for Injection (SC) (30% Regular Insulin Human/70% Isophane Insulin Human)
|
Intermediate-Acting Insulin
|
Wockhardt Limited
|
India
|
Automatic Renewal (E-AR)
|
15 November 2023
|
10 February 2029
|
| View |
|
BRP-055
|
Insulin Glargine
|
Toujeo
|
300 Units (equivalent to 10.91 mg)/mL
|
Powder For Oral Suspension Solution for
Injection (SC)
|
Antidiabetics
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
Initial (from Monitored Release)
|
27 June 2022
|
23 June 2026
|
| View |
|
BRP-056
|
Insulin Glargine
|
Lantus XR
|
300 Units (equivalent to 10.91 mg)/mL
|
Solution for Injection (SC)
|
Insulins and Analogues
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
Initial Variation]
|
19 April 2024
|
19 April 2029
|
| View |
|
BRP-057
|
Human Albumin
|
Humal
|
20% (0.2 g/mL)
|
Solution For Intravenous Infusion
|
Plasma Fraction for Specific Use
|
Reliance Life Sciences Pvt. Ltd.
|
India
|
Renewal
|
08 December 2023
|
09 May 2029
|
| View |
|
BRP-057-01
|
Human Albumin
|
Rescuerel
|
20% (0.2 g/mL)
|
Solution for Intravenous Infusion
|
Blood substitutes and plasma protein fractions
|
Reliance Life Sciences Pvt. Ltd. (Plant II)
|
India
|
Renewal
|
23 January 2024
|
09 May 2029
|
| View |
|
BRP-057-02
|
Human Albumin
|
Alburel
|
20 % (0.2 g/mL)
|
Solution For Intravenous Infusion
|
Blood substitutes and plasma protein fractions
|
Reliance Life Sciences Pvt. Ltd. (Plant II) (Plant 4B)
|
India
|
Renewal
|
18 January 2024
|
09 May 2029
|
| View |
|
BRP-057-03
|
Human Albumin
|
Hulbumine
|
20% (0.2 g/mL)
|
Solution For Intravenous Infusion
|
Blood substitutes and plasma protein fractions
|
Reliance Life Sciences Pvt. Ltd.
|
India
|
Renewal
|
14 January 2024
|
09 May 2029
|
| View |
BRP-059_PI_01.pdf
|
BRP-059
|
Insulin Glargine
|
Basaglar Kwikpen
|
100 Units/mL
|
Solution For Injection (SC)
|
-
|
Eli Lilly Italia S.p.A.
|
Italy
|
Monitored Release (Variation)
|
21 November 2022
|
21 November 2027
|